Pharmacodynamic Effects of Sacubitril/Valsartan on Natriuretic Peptides, Angiotensin and Neprilysin

NCT03553303 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2019-08-29

No results posted yet for this study

Summary

The study measure multiple neurohormones in patients with heart failure being treated with Sacubitril/Valsartan in increasing doses over an 8 week period.

Conditions

  • Heart Failure, Systolic

Interventions

DRUG

Sacubitril / Valsartan Oral Tablet

Increasing doses of Sacubitril/Valsartan

Sponsors & Collaborators

  • Oslo University Hospital

    lead OTHER

Principal Investigators

  • Christian Hall, MD PhD · University of Oslo

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-10-16
Primary Completion
2022-05-31
Completion
2022-05-31

Countries

  • Norway

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03553303 on ClinicalTrials.gov